$AGN (Allergan plc)

$AGN {{ '2016-08-08T11:43:55+0000' | timeago}} • Announcement

$AGN said its flagship Botox revenues rose 14% to $719.7MM in 2Q16 from last year, on continued market share expansion, enhanced promotional focus and overall continued strong demand for the product. Restasis revenue grew 20.2% to $390.6MM on continued strong promotional efforts. Fillers' revenues increased 14.7% $224.9MM.

$MYL {{ '2017-10-17T16:40:23+0000' | timeago}} • Announcement

$MYL announced that the United States District Court for the Eastern District of Texas issued a decision finding all asserted claims of the patents relating to Restasis invalid. The Court recognized that $AGN's patent protection for Restasis ended in 2014.

$AGN {{ '2017-10-16T21:26:34+0000' | timeago}} • Announcement

Drugmaker $AGN gets an adverse effect from the U.S. District Court for the Eastern District of Texas. The judge invalidated Allergan's Restasis patent deal, which was signed with the Mohawk Tribe in the last month. Allergan plans to appeal the ruling. Restasis, a dry-eye treatment drug,  generated $1.5Bil of revenues for Allergan in 2016.

$AGN {{ '2017-10-12T22:44:22+0000' | timeago}} • Announcement

$AGN, which inked a controversial patent deal with Mohawk Tribe, reached a patent litigation settlement on its dry eye treatment drug Restasis with InnoPharma, a unit of $PFE. The litigation, which was filed in Sept. 2015 by Allergan, will be withdrawn and Allergan will grant license to InnoPharma to market Restasis from Feb. 2024 or earlier.

$AGN {{ '2017-10-10T18:02:39+0000' | timeago}} • Announcement

FDA accepts to review $AGN's New Drug Application seeking approval for ulipristal acetate, an investigational drug for the treatment of abnormal bleeding in women with uterine fibroids. Allergan expects the action date to occur in 1H18. According to the Agency for Healthcare Research and Quality (AHRQ), 26MM women in U.S. have got uterine fibroids.

$AGN {{ '2017-10-02T17:04:07+0000' | timeago}} • Announcement

FDA accepts to do a priority review of $AGN's antibiotic drug Avycaz. The supplemental New Drug Application (sNDA) filed by Allergan seeks to expand the usage of Avycaz for the treatment of patients with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. The FDA is expected to take action on the filing in 1Q18.

$AGN {{ '2017-09-25T15:26:35+0000' | timeago}} • Announcement

$AGN CFO Tessa Hilado has decided to retire from the company. Allergan has initiated a search to fill the position. Hilado, who joined the company in Dec 2014, will continue in her current role until a successor is named to ensure a smooth transition.

$AGN {{ '2017-09-25T12:23:08+0000' | timeago}} • Announcement

$AGN has authorized a new $2Bil share repurchase program, and has affirmed its commitment to increasing its regular quarterly cash dividend annually. The company also affirmed its 3Q17 revenue projection, which was issued on Aug 3, 2017.

$AGN {{ '2017-09-22T21:53:16+0000' | timeago}} • Announcement

$AGN received a Refusal to File letter from the US FDA on its Supplemental New Drug Application (sNDA) for Vraylar for treatment of negative symptoms associated with schizophrenia in adult patients. VRAYLAR is an oral antipsychotic approved in the US to treat schizophrenia. The FDA said the sNDA was not sufficient to permit a substantive review.

$AGN {{ '2017-09-22T14:30:34+0000' | timeago}} • Announcement

$AGN announced top-line results from new data for the Centaur Phase 2b study which supports the anti-fibrotic efficacy and safety of Cenicriviroc (CVC) for the treatment of liver fibrosis in adults with NASH. $AGN is currently enrolling patients in a 2,000 patient phase 3 clinical trial of CVC called the Aurora trial.

$AMGN {{ '2017-09-14T19:26:48+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi for the treatment of five types of cancer. Amgen and Allergan's bevacizumab biosimilar is also undergoing review by the European Medicines Agency, following a Marketing Authorization Application submitted in December 2016.

$AMGN {{ '2017-09-14T19:26:21+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. The approval was based on totality of evidence from global development program showing Mvasi is highly similar to Avastin. Mvasi is the first anti-cancer biosimilar, as well as first bevacizumab biosimilar, approved by the FDA.

$AGN {{ '2017-09-08T19:54:30+0000' | timeago}} • Announcement

$AGN transferred all patents for its dry eye treatment drug Restasis to the St. Regis Mohawk tribe to protect the drug patents. The tribe has granted Allergan back an exclusive license for the drug. As per the agreement, the tribe will get $13.75MM as one-time payment, and potentially $15MM annually in royalties.

$AGN {{ '2017-08-29T10:53:21+0000' | timeago}} • Announcement

$AGN and its subsidiaries reached a settlement regarding its litigation with Famy Care Ltd. relating to the company's patent covering Restasis (Cyclosporine Ophthalmic Emulsion). All Famy Care litigation regarding Restasis patents will be dismissed and Famy Care will terminate its pending petitions for Inter Parties Review.

$AGN {{ '2017-08-03T19:43:47+0000' | timeago}} • Announcement

"With our strong first half performance and solid outlook for the remainder of the year, we are raising our full-year guidance,” said CEO Brent Saunders. For FY17, $AGN expects sales to be $15.85-16.05Bil, up from the prior estimate of $15.8-16.0Bil. GAAP loss per share is expected to be $10.80-11.20 versus the previous range of $9.70-10.20.

$AGN {{ '2017-08-03T18:43:48+0000' | timeago}} • Announcement

$AGN, which owns 9.9% stake in $TEVA, reported a wider loss in 2Q17, hurt by the loss of patent exclusivity and lower revenues from certain drugs. Net loss attributable to ordinary shareholders was $796MM or $2.37 per share compared to $571MM or $1.44 per share a year ago. However, revenue rose 9% to $4.01Bil and adjusted EPS increased 20% to $4.02.

$AGN {{ '2017-08-03T14:32:45+0000' | timeago}} • Infographic

$AGN Allergan Plc Earnings AlphaGraphic: Q2 2017 Highlights

$AGN {{ '2017-08-02T17:05:08+0000' | timeago}} • Announcement

$AGN's BoD declared 3Q17 cash dividend of $0.70 per ordinary share. The dividend will be paid on Sept. 15, 2017 to shareholders of record at the close of business on Aug. 18, 2017.

$AMGN {{ '2017-07-31T13:27:43+0000' | timeago}} • Announcement

$AMGN and $AGN announced the submission of a Biologics License Application (BLA) to the FDA for ABP 980, a biosimilar candidate to Herceptin (trastuzumab). These two companies are collaborating on four oncology biosimilar medicines, including ABP 980 which is the second to be submitted for FDA approval.

$AGN {{ '2017-07-19T15:54:53+0000' | timeago}} • Announcement

$AGN appointed Joseph Boccuzi to its BoD, effective immediately. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with the global executive search and leadership consulting firm.

$AMGN {{ '2017-07-13T12:24:26+0000' | timeago}} • Announcement

$AMGN and $AGN announced they will discuss data supporting the ABP 215 Biologics License Application (BLA) with FDA's Oncologic Drugs Advisory Committee. ABP 215 is a biosimilar candidate to Avastin (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.

Recent Transcripts

UNH (UnitedHealth Group Incorporated)
Tuesday, October 17 2017 - 12:45pm
NKTR (Nektar Therapeutics)
Tuesday, August 8 2017 - 9:00pm
TBPH (Theravance Biopharma, Inc.)
Tuesday, August 8 2017 - 9:00pm
ZGNX (Zogenix, Inc.)
Tuesday, August 8 2017 - 8:30pm
DRRX (DURECT Corporation)
Tuesday, August 8 2017 - 8:30pm
XNCR (Xencor, Inc.)
Monday, August 7 2017 - 8:30pm
ARNA (Arena Pharmaceuticals Inc)
Monday, August 7 2017 - 8:30pm
ABC (AmerisourceBergen Corporation)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Wednesday, August 2 2017 - 8:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
ZIOP (ZIOPHARM Oncology, Inc.)
Monday, July 31 2017 - 8:30pm
SNSS (Sunesis Pharmaceuticals, Inc.)
Thursday, July 27 2017 - 6:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
ALKS (Alkermes plc)
Thursday, July 27 2017 - 12:30pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
UNH (UnitedHealth Group Incorporated)
Tuesday, July 18 2017 - 12:45pm

AlphaGraphics you may like